Provided by Tiger Fintech (Singapore) Pte. Ltd.

Xenetic Biosciences Inc

2.96
-0.1435-4.63%
Post-market: 2.960.00000.00%16:12 EDT
Volume:1.63K
Turnover:4.97K
Market Cap:4.56M
PE:-1.24
High:3.18
Open:3.18
Low:2.91
Close:3.10
Loading ...

Xenetic Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
15 May

Xenetic Biosciences Reports Q1 2025 Results: Revenue Up 16.1% to $0.6M; Net Loss at $0.9M

Reuters
·
14 May

Xenetic Biosciences Q1 EPS $(0.59) Beats $(0.72) Estimate, Sales $593.26K Miss $670.00K Estimate

Benzinga
·
14 May

Xenetic Biosciences Inc. Files Amendment to 10-K Annual Report

Reuters
·
14 May

Xenetic Biosciences Inc expected to post a loss of 72 cents a share - Earnings Preview

Reuters
·
06 May

Xenetic Biosciences (XBIO) Receives a Hold from H.C. Wainwright

TIPRANKS
·
09 Apr

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

ACCESS Newswire
·
09 Apr

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma

ACCESS Newswire
·
26 Mar

Xenetic Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
20 Mar

Xenetic Biosciences Net Loss For The Year Ended December 31, 2024 Was ~$4M; Ended The Year With ~$6.2M Of Cash

Benzinga
·
19 Mar

Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results

ACCESS Newswire
·
19 Mar

Xenetic Biosciences Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
18 Mar

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses

ACCESS Newswire
·
13 Mar

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

ACCESS Newswire
·
27 Feb

Xenetic extends research collaboration with University of Virginia

TIPRANKS
·
16 Dec 2024